Clinical trial
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
NCT01743651
Study timeline
Study start (unknown)2012-11-01Date precision: month
Registry last updated2022-04-25
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Spasticityunresolved
Multiple Sclerosisunresolved
Interventions
Sponsors & collaborators
RVL Pharmaceuticals, Inc.lead sponsor
Osmotica Pharmaceutical US LLCcollaborator
Mapped research locations
New YorkNew York, United States3Saint PetersburgRussia3KharkivUkraine3MoscowRussia2BaltimoreMaryland, United States1San AntonioTexas, United States1SeattleWashington, United States1PittsburghPennsylvania, United States1CincinnatiOhio, United States1TampaFlorida, United States1AuroraColorado, United States1Ann ArborMichigan, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01743651 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.